Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Age and sex-specific reference intervals for prooxidant-antioxidant balance, anti-heat-shock protein 27 (anti-hsp27), and routine laboratory tests in the middle-aged adult population.
Ghazizadeh H, Bohn MK, Yaghooti-Khorasani M, Ghaffarian-Zirak R, Valizadeh M, Saberi-Karimian M, Safarian H, Kamel-Khodabandeh A, Zare-Feyzabadi R, Timar A, Mohammadi-Bajgiran M, Oladi MR, Gachpazan M, Rohban M, Esmaily H, Ferns GA, Adeli K, Ghayour-Mobarhan M. Ghazizadeh H, et al. Biotechnol Appl Biochem. 2022 Jun;69(3):1300-1310. doi: 10.1002/bab.2203. Epub 2021 Aug 7. Biotechnol Appl Biochem. 2022. PMID: 34028875
Additionally, after partitioning the participants based on the BMI with a cutoff point of 25 kg/m(2) , only the levels of hs-CRP were positively associated with higher BMI (RI for BMI>25: 0.51-7.85 mg/L and for BMI<25: 0.40-4.46 mg/L). ...
Additionally, after partitioning the participants based on the BMI with a cutoff point of 25 kg/m(2) , only the levels of hs-CRP were …
Efficacy and safety of N-acetyl-L-leucine in patients with ataxia telangiectasia: A randomized, double-blind, placebo-controlled, crossover clinical trial.
Beyraghi-Tousi M, Sahebkar A, Houra M, Sarvghadi P, Jamialahmadi T, Bagheri R, Tavallaie S, Gumpricht E, Saberi-Karimian M. Beyraghi-Tousi M, et al. Eur J Paediatr Neurol. 2024 Apr 22;50:57-63. doi: 10.1016/j.ejpn.2024.04.009. Online ahead of print. Eur J Paediatr Neurol. 2024. PMID: 38669738
NALL treatment had no significant effects on SARA, SCAFI-9HPT (9-hole peg test) nondominant, SCAFI-9HPT dominant, or SCAFI-8WMT (8 m walking time) (p > 0.05). Our patient's Physical Health score in Child self-report and Parent proxy-report did not significantly change i …
NALL treatment had no significant effects on SARA, SCAFI-9HPT (9-hole peg test) nondominant, SCAFI-9HPT dominant, or SCAFI-8WMT (8 m …